GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) reported a 2.6% year-on-year decline in revenue for the second quarter of fiscal year 2026, primarily due to supply chain disruptions and GST reform impacts. Despite these challenges, the company managed to improve its EBITDA margins and maintain market share in key segments.

Financial Performance

GSK Pharma's Q2 FY2026 financial results showcase a mixed performance:

Key Highlights

• Supply Chain Disruption: A fire incident at a key contract manufacturing organization (CMO) impacted revenue by approximately ₹40.00 crores.
• GST Reform Impact: Transitionary effects of GST reforms resulted in a ₹30.00-32.00 crores revenue impact.
• Margin Improvement: Despite revenue challenges, EBITDA margins improved by 250 basis points to 34.4%, driven by cost savings and better product mix.
• Market Share: The company maintained its market share at 27.6%.
• Oncology Launch: GSK Pharma launched its oncology business on August 15, 2025, introducing Jemperli for endometrial cancer and Zejula for ovarian cancer.

Segment Performance

• General Medicines: Faced headwinds due to supply issues and softer market growth in acute segments.
• Vaccines: Demonstrated strong double-digit growth in both pediatric and adult segments.
• Specialty Products: Nucala and Trelegy grew over 20%.

Management Commentary

Bhushan Akshikar, Managing Director of GSK Pharma, stated, "Moving forward from Q3 onwards, we definitely expect to not only stabilize but start building the inventories. We have very robust business continuity plans in place."

Juby Chandy, Chief Financial Officer, added, "We will be able to sustain the margins. We are seeing stable prices on raw materials and hence we will be able to sustain the gross margins."

Future Outlook

• The company remains committed to its double-digit growth ambition for the coming quarters.
• Supply constraints are expected to be resolved from Q3 onwards.
• GSK Pharma continues to focus on expanding its presence in specialty areas, including oncology.
• The company is participating in 16 global trials of its assets in India, aiming to accelerate the launch of innovative medicines and vaccines.

As GSK Pharma approaches its 102nd year of operations in India, it continues to navigate challenges while maintaining its focus on growth and innovation in the pharmaceutical sector.

GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) has reported a mixed set of financial results for the second quarter ended September 30, with a decline in revenue but an increase in profitability.

Financial Highlights

Revenue Performance

GSK Pharma experienced a decline in revenue from operations, which decreased to ₹97,994.00 lakhs from ₹101,077.00 lakhs in the same quarter last year, representing a 3.05% year-over-year decrease. For the six-month period, revenue dropped to ₹178,511.00 lakhs from ₹182,542.00 lakhs year-over-year.

Profitability Improvements

Despite the revenue decline, the company managed to improve its profitability:

• Net Profit: Increased to ₹25,500.00 lakhs from ₹23,640.00 lakhs, showing a 7.87% year-over-year growth.

Earnings Per Share

Basic and diluted earnings per share for the quarter stood at ₹18.06 compared to ₹27.14 in the corresponding quarter last year, marking a decrease of 33.46%.

Solar Power Investment

The company's Board has approved an investment of ₹1.74 crores for a Solar Power project at its Nashik plant under the Group Captive mechanism. This investment involves:

• Acquiring a 26% shareholding in CleanMax Galapagos Private Limited, a special purpose vehicle.
• The SPV will supply 4.95 MWp capacity renewable energy.

This move aligns with the growing trend of pharmaceutical companies investing in sustainable energy solutions to reduce their carbon footprint and operational costs.

Exceptional Items

GSK Pharma reported exceptional items credit of ₹264.00 lakhs from profit on sale of surplus residential properties.

Conclusion

GlaxoSmithKline Pharmaceuticals' Q2 results present a mixed picture. While the company faces challenges in revenue growth, it has managed to improve its bottom line. The investment in solar power demonstrates a commitment to sustainability and potentially long-term cost reduction. As the pharmaceutical landscape continues to evolve, GSK Pharma's ability to maintain profitability while addressing revenue challenges will be crucial for its future performance.